What is Array Comparative Genomic Hybridisation (aCGH)?

Introduction: What is Array Comparative Genomic Hybridisation?

In the rapidly evolving landscape of Reproductive Genetics, understanding the building blocks of our biology has never been more precise. One of the most significant breakthroughs in this field is Array Comparative Genomic Hybridisation (aCGH). Often described as a high-resolution “molecular microscope”, aCGH has become an indispensable tool in modern clinical diagnostics.

At its core, the process of Hybridisation allows scientists to examine the entire set of human chromosomes in extraordinary detail. Unlike traditional methods that only look for large structural changes, aCGH scans the genome for tiny imbalances—specifically gains or losses of genetic material—that could impact a person’s health or development.

The power of this technology is particularly evident in PGT (Preimplantation Genetic Testing), where it is used to ensure the chromosomal health of embryos. By employing the principles of Hybridisation, clinicians can identify micro-deletions or duplications that were previously invisible, providing prospective parents and patients with a level of diagnostic certainty that was once unimaginable. Whether used to investigate developmental delays or to support a healthy pregnancy, aCGH represents the gold standard in identifying the subtle genetic variations that make us who we are.

The Science of Hybridisation: How the aCGH Test Works

Array Comparative Genomic Hybridisation (aCGH) works by comparing two sets of DNA to identify subtle genetic differences. The method relies on a natural biological process called hybridisation, where complementary DNA strands bind together like biological “velcro”. By comparing a patient’s DNA with a reference sample, scientists can detect missing or extra pieces of genetic material across the genome.

Preparation of DNA Samples

Two DNA samples are prepared for analysis: the patient’s DNA (test sample) and a reference DNA sample from a healthy individual. These samples provide the basis for identifying potential genetic imbalances.

Fluorescent Colour Labelling

Each DNA sample is labelled with a different fluorescent dye. Typically, the patient’s DNA is tagged in red, while the reference DNA is labelled in green, allowing scientists to visually distinguish between the two during analysis.

Hybridisation on the Microarray

Both DNA samples are placed onto a specialised glass slide called a microarray. The slide contains thousands of probes representing regions of the human genome, where the red and green DNA strands compete to bind through hybridisation.

Laser Scanning and Data Detection

A high‑resolution laser scanner reads the microarray slide and measures the intensity of the red and green signals. The ratio between these signals reveals whether genetic material is balanced or altered.

Colour Interpretation

Yellow signals indicate equal binding of patient and reference DNA, suggesting normal genetic balance. Green signals suggest a deletion in the patient’s genome, while red signals indicate a duplication of genetic material.

Detecting Copy Number Variants

By analysing these colour patterns, clinicians can identify copy number variants (CNVs)—small duplications or deletions in DNA that may be linked to genetic conditions and are too small to detect using traditional microscopy.

Key Insight:
Hybridisation-based microarray technology allows scientists to compare genomes with remarkable precision. Through colour-coded signals and high‑resolution analysis, aCGH reveals subtle genetic variations that provide valuable insight into an individual’s unique genetic profile.

Why Have I Been Offered an aCGH Test?

If your consultant or GP has recommended an aCGH test, it is usually because they need a more detailed look at the genetic information than a standard test can provide. In the UK, the NHS and private genetics clinics frequently use this technology as a first-line investigation for several key reasons.

Investigating Developmental Concerns

One of the most common reasons for offering this test is to find an underlying cause for developmental delay or learning difficulties. While many conditions have visible symptoms, the root cause often lies in tiny chromosomal imbalances that only the high-resolution process of Hybridisation can detect. Identifying these changes can help families access the right support and specialist care.

Congenital Abnormalities and Health Issues

If a child is born with physical differences—often referred to as congenital abnormalities—or has unexplained health problems like seizures or heart defects, an aCGH test is often prioritised. By analysing the patient’s DNA against a healthy reference, specialists can determine if a micro-deletion or duplication is responsible for these physical manifestations.

Prenatal Screening and Pregnancy

During pregnancy, an aCGH test may be offered if an ultrasound scan has picked up a physical variation in the foetus. Because of its precision, this method is significantly more informative than traditional karyotyping. It provides expectant parents with clearer answers regarding the health of the pregnancy, often following an amniocentesis or CVS (Chorionic Villus Sampling) procedure.

Providing a “Diagnostic End-Point”

For many patients, being offered an aCGH test is the final step in a long journey to find a diagnosis. In the medical community, this is sometimes called ending the “diagnostic odyssey.” Even if the result does not change the immediate clinical treatment, having a definitive answer allows families to:

Understand the risk of the condition recurring in future pregnancies.
Connect with specific support groups and national charities.
Access specialised medical monitoring tailored to their specific genetic profile.

By utilizing the power of Hybridisation, healthcare providers can move beyond guesswork and provide personalised medical insights based on your unique genetic code.

What Can aCGH Detect That Other Tests Cannot?

To appreciate the power of Array Comparative Genomic Hybridisation, it is helpful to compare it with traditional methods like G-banded karyotyping. While karyotyping has been the standard for decades, it has limitations in resolution that aCGH easily overcomes through the precision of Hybridisation.

Core technologies that enable scientists to analyse genomic data and drive discoveries in bioinformatics.

The Resolution Revolution: A Change in Scale

Comparing DNA, RNA, and protein sequences.

Tools such as BLAST, Clustal Omega, and MUSCLE allow researchers to compare biological sequences, identify similarities, and explore evolutionary relationships. They are widely used to locate genes and detect variations across genomes.

Identifying Micro-deletions and Micro-duplications

Processing large‑scale sequencing data.

Software such as Bowtie, BWA, and SAMtools maps millions of short DNA reads to reference genomes. These tools support genome assembly, variant detection, and mutation analysis in genetic and disease research.

Why Precision Matters for Patients

Large repositories of genomic information.

Databases such as GenBank, UniProt, and Ensembl store vast collections of DNA, protein, and genome annotations. They allow scientists worldwide to access reliable datasets for comparative analysis and research.

Higher Diagnostic Yield

Generating large‑scale genomic data.

Platforms such as Illumina and Oxford Nanopore rapidly sequence entire genomes, producing the massive datasets analysed by bioinformatics pipelines and enabling modern genomic research.

Specific Mapping

Visualising molecular structures.

Tools such as PyMOL and Chimera allow scientists to visualise three‑dimensional protein structures, helping researchers understand molecular function, study mutations, and support drug discovery.

Speed and Objectivity

Advanced pattern discovery in biological data.

Artificial intelligence algorithms analyse massive biological datasets to predict gene function, detect hidden patterns, and model protein structures. Breakthroughs such as AlphaFold have significantly advanced molecular biology research.

In summary, while older tests are still useful for seeing “the big picture,” aCGH is the essential tool for uncovering the fine details that are often the key to understanding complex genetic conditions.

Automating bioinformatics pipelines.

Platforms such as Galaxy and Nextflow allow researchers to automate complex analytical workflows, ensuring analyses remain reproducible, transparent, and easily shared across laboratories.

Key Takeaway:

Bioinformatics combines powerful computational tools with biological data to accelerate scientific discovery. From sequence analysis and genome mapping to AI‑driven predictions, these technologies form the foundation of modern genomic research and precision medicine.

Understanding Your Results: From Normal to Uncertain

Receiving the results of an aCGH test can be a complex emotional experience. Because the process of Hybridisation is so sensitive, it can reveal various types of information. Your genetic report will typically fall into one of three main categories.

Normal Result (No Clinically Significant Changes)

A “normal” result means that the Hybridisation process did not detect any extra or missing pieces of genetic material that are known to cause health problems.

What this means: While this is often reassuring, it does not completely rule out a genetic condition. Some conditions are caused by tiny changes within a single gene (point mutations) which aCGH cannot see.
Next Steps: Your consultant will discuss whether further, more specific sequencing tests are needed.

Pathogenic Result (A Clear Finding)

A “pathogenic” or “clinically significant” result means that a change—either a deletion or a duplication—was found that is known to be linked to specific health or developmental challenges.

What this means: This result provides a definitive explanation for the symptoms or concerns being investigated.
Next Steps: This information is vital for Reproductive Genetics planning and allows doctors to create a specialised care plan tailored to the specific condition identified.

Variant of Uncertain Significance (VOUS)

Sometimes, the Hybridisation analysis picks up a change in the DNA that has not been seen or documented enough in the medical community to be certain of its effect. This is called a VOUS.

What this means: It is currently unclear whether this change is just a natural, harmless variation (like having a different eye colour) or if it is the cause of the health concern.
Next Steps: To understand a VOUS, doctors often ask to test the biological parents. If one of the parents has the same variation and is healthy, it is much more likely that the change is a harmless family trait.

Importance of Professional Guidance

It is essential to remember that these results should always be interpreted by a qualified clinical geneticist or a genetic counsellor. In the UK, these specialists are trained to help you understand the implications of the Hybridisation findings for both your health and that of your family members.

The Testing Process: What to Expect in the Clinic

Understanding the practical steps of an aCGH test can help ease any concerns you may have about the procedure. In most UK clinics and NHS trust hospitals, the process is straightforward and designed to be as non-invasive as possible.

Step 1: The Sample Collection

The first step in the Hybridisation journey is obtaining your genetic material. This is typically done in one of two ways:

Blood Sample: This is the most common method for adults and children. A small amount of blood is taken from a vein, usually in the arm.
Saliva or Cheek Swab: In cases where a blood draw is difficult (such as with very young infants), a saliva sample or a gentle swab of the inside of the cheek may be used instead.
Prenatal Samples: If the test is being performed during pregnancy, the sample is obtained via amniocentesis or Chorionic Villus Sampling (CVS).

Step 2: Laboratory Preparation

Once your sample reaches the laboratory, scientists extract the DNA. This DNA then undergoes the Hybridisation process we described earlier, where it is compared against a reference sample on a microarray chip. This stage requires a highly controlled environment to ensure the results are accurate and reliable.

Step 3: Analysis and Reporting

After the Hybridisation is complete, specialised software scans the chip. A clinical scientist then reviews the data to identify any significant gains or losses of genetic material. This meticulous review is part of what ensures the high standards of Reproductive Genetics diagnostics in the UK.

How Long Will I Wait for Results?

Waiting for genetic results can be a period of uncertainty. In the UK, the turnaround time can vary depending on the urgency and the specific laboratory:

Routine Cases: Generally, you can expect results within 3 to 6 weeks.
Urgent Cases (e.g., Prenatal): These are often prioritised and may be returned within 7 to 10 working days.

Following Up

Once the report is finalised, it is sent back to the consultant or genetic counsellor who requested the test. They will then arrange a follow-up appointment—either in person or via a video consultation—to explain the findings of the Hybridisation analysis and what they mean for you and your family.

Conclusion

While the science behind Hybridisation is sophisticated, its purpose is simple: to provide clarity. By identifying micro-deletions and duplications with high precision, aCGH empowers you and your healthcare providers to make informed decisions about your health and the health of your family.

Remember, you are not alone in this process. The combination of advanced technology and professional guidance ensures that you have the support needed to move forward with confidence.

Clarity Through Precision:
aCGH identifies micro-deletions and micro-duplications with high accuracy, turning complex genetic data into clear, actionable insights.

Informed Decision-Making:
These precise results empower you and your healthcare team to make confident, evidence-based decisions for your health and your family’s wellbeing.

Technology + Guidance:
Advanced laboratory methods combined with professional genetic counselling ensure you’re supported at every step.

You Are Not Alone:
From testing to interpretation, a dedicated team is available to guide you through the process with care and expertise.

Moving Forward With Confidence:
Clear results and expert support help you plan next steps with reassurance and clarity.

Book Your Consultation with Dr Karimiani

Dr Ehsan Karimiani

Dr Ehsan Karimiani (MD, MRes, PhD) is a distinguished London-based Clinical Geneticist and a leading figure in the field of rare inherited conditions. With over a hundred scientific publications to his name, he masterfully bridges advanced clinical expertise with internationally recognised genomic research. Dr. Karimiani specialises in risk assessment, cancer genetics, and delivering clear, tailored guidance to families navigating complex hereditary information. A true global advocate, he is committed to raising the profile of medical genomics and promoting the vital role of genetic counselling across diverse international communities.